Suppr超能文献

新型第四代头孢菌素头孢噻利对中国临床重要病原菌的活性

Activity of a New Fourth-Generation Cephalosporin, Cefoselis, Against Clinically Important Bacterial Pathogens in China.

作者信息

Cheng Jing-Wei, Su Jian-Rong, Xiao Meng, Yu Shu-Ying, Zhang Ge, Zhang Jing-Jia, Yang Yang, Duan Si-Meng, Kudinha Timothy, Yang Qi-Wen, Xu Ying-Chun

机构信息

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Center of Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

出版信息

Front Microbiol. 2020 Feb 28;11:180. doi: 10.3389/fmicb.2020.00180. eCollection 2020.

Abstract

The objective of this study was to systematically evaluate the activity of cefoselis and other comparators against common bacterial pathogens collected from 18 hospitals across China. Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method following Clinical and Laboratory Standards Institute (CLSI) guidelines. Cefoselis showed poor activity against extended-spectrum β-lactamase (ESBL)-producing , , and , with susceptibility rates of < 10% each, while the susceptibility rates of this antibiotic against non-ESBL-producing strains of these organisms were 100%, 94.3%, and 97.0%, respectively. Cefoselis exhibited susceptibility rates of 56.7-83.3% against other tested Enterobacteriaceae isolates. For and isolates, the susceptibility rates to cefoselis were 18.7% and 73.3%, respectively. All methicillin-resistant (MRSA) strains were resistant to cefoselis, while all methicillin-sensitive (MSSA) strains were susceptible to this antibiotic. In conclusion, cefoselis showed good activity against non-ESBL-producing , , and , MSSA, and was also potent against Enterobacteriaceae, , and .

摘要

本研究的目的是系统评估头孢洛林及其他对照药物对从中国18家医院收集的常见细菌病原体的活性。按照临床和实验室标准协会(CLSI)指南,采用肉汤微量稀释法测定最低抑菌浓度(MIC)。头孢洛林对产超广谱β-内酰胺酶(ESBL)的大肠埃希菌、肺炎克雷伯菌和奇异变形杆菌活性较差,药敏率均<10%,而该抗生素对这些菌的非产ESBL菌株的药敏率分别为100%、94.3%和97.0%。头孢洛林对其他受试肠杆菌科分离株的药敏率为56.7 - 83.3%。对于阴沟肠杆菌和产气肠杆菌分离株,头孢洛林的药敏率分别为18.7%和73.3%。所有耐甲氧西林金黄色葡萄球菌(MRSA)菌株均对头孢洛林耐药,而所有甲氧西林敏感金黄色葡萄球菌(MSSA)菌株均对该抗生素敏感。总之,头孢洛林对非产ESBL的大肠埃希菌、肺炎克雷伯菌和奇异变形杆菌、MSSA表现出良好活性,对肠杆菌科、阴沟肠杆菌和产气肠杆菌也有较强活性。

相似文献

1
Activity of a New Fourth-Generation Cephalosporin, Cefoselis, Against Clinically Important Bacterial Pathogens in China.
Front Microbiol. 2020 Feb 28;11:180. doi: 10.3389/fmicb.2020.00180. eCollection 2020.
6
Patterns of Drug-Resistant Bacteria in a General Hospital, China, 2011-2016.
Pol J Microbiol. 2019;68(2):225-232. doi: 10.33073/pjm-2019-024.

引用本文的文献

本文引用的文献

1
The Continuing Threat of Methicillin-Resistant .
Antibiotics (Basel). 2019 May 2;8(2):52. doi: 10.3390/antibiotics8020052.
2
Current Status and Trends of Antibacterial Resistance in China.
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S128-S134. doi: 10.1093/cid/ciy657.
3
Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Expert Rev Anti Infect Ther. 2018 Mar;16(3):205-218. doi: 10.1080/14787210.2018.1436966. Epub 2018 Feb 9.
4
Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.
Biomed Res Int. 2016;2016:2475067. doi: 10.1155/2016/2475067. Epub 2016 May 5.
5
Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
Expert Opin Pharmacother. 2016;17(7):953-67. doi: 10.1517/14656566.2016.1154538. Epub 2016 Mar 3.
10
Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.
Clin Infect Dis. 2014 Jan;58 Suppl 1:S20-7. doi: 10.1093/cid/cit614.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验